| Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis AA Agyeman, KL Chin, CB Landersdorfer, D Liew, R Ofori-Asenso Mayo Clinic Proceedings 95 (8), 1621-1631, 2020 | 573 | 2020 |
| Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform … CC Butler, FDR Hobbs, OA Gbinigie, NM Rahman, G Hayward, ... The Lancet 401 (10373), 281-293, 2023 | 338 | 2023 |
| Irrational use of medicines—a summary of key concepts R Ofori-Asenso, AA Agyeman Pharmacy 4 (4), 35, 2016 | 330 | 2016 |
| Overweight and obesity epidemic in Ghana—a systematic review and meta-analysis R Ofori-Asenso, AA Agyeman, A Laar, D Boateng BMC public health 16, 1-18, 2016 | 295 | 2016 |
| Hepatitis B in Ghana: a systematic review & meta-analysis of prevalence studies (1995-2015) R Ofori-Asenso, AA Agyeman BMC infectious diseases 16, 1-15, 2016 | 207 | 2016 |
| Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis AA Agyeman, R Ofori-Asenso Annals of clinical microbiology and antimicrobials 15, 1-17, 2016 | 158 | 2016 |
| A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections AA Agyeman, PJ Bergen, GG Rao, RL Nation, CB Landersdorfer International journal of antimicrobial agents 55 (1), 105833, 2020 | 105 | 2020 |
| Perspective: Does personalized medicine hold the future for medicine? AA Agyeman, R Ofori-Asenso Journal of Pharmacy and Bioallied Sciences 7 (3), 239-244, 2015 | 102 | 2015 |
| Tuberculosis—an overview AA Agyeman, R Ofori-Asenso Journal of Public Health and Emergency 1 (1), 2017 | 86 | 2017 |
| Prevalence of HIV and hepatitis B coinfection in Ghana: a systematic review and meta-analysis AA Agyeman, R Ofori-Asenso AIDS research and therapy 13, 1-9, 2016 | 72 | 2016 |
| Epidemiology of hepatitis C virus in Ghana: a systematic review and meta-analysis AA Agyeman, R Ofori-Asenso, A Mprah, G Ashiagbor BMC infectious diseases 16, 1-14, 2016 | 55 | 2016 |
| Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis R Ofori-Asenso, O Ogundipe, AA Agyeman, KL Chin, M Mazidi, Z Ademi, ... Ecancermedicalscience 14, 2020 | 51 | 2020 |
| Metabolic syndrome in apparently “healthy” Ghanaian adults: A systematic review and meta‐analysis R Ofori-Asenso, AA Agyeman, A Laar International journal of chronic diseases 2017 (1), 2562374, 2017 | 51 | 2017 |
| Will COVID‐19 be a litmus test for post‐Ebola sub‐Saharan Africa? AA Agyeman, A Laar, R Ofori‐Asenso Journal of Medical Virology 92 (9), 1373, 2020 | 38 | 2020 |
| A review of injection and antibiotic use at primary health care (public and private) centers in Africa R Ofori-Asenso, AA Agyeman Journal of Pharmacy and Bioallied Sciences 7 (3), 175-180, 2015 | 28 | 2015 |
| Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2× 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 DM Lowe, LAK Brown, K Chowdhury, S Davey, P Yee, F Ikeji, ... PLoS Medicine 19 (10), e1004120, 2022 | 25 | 2022 |
| Evaluation of meropenem‐ciprofloxacin combination dosage regimens for the pharmacokinetics of critically ill patients with augmented renal clearance AA Agyeman, KE Rogers, JR Tait, PJ Bergen, CM Kirkpatrick, SC Wallis, ... Clinical Pharmacology & Therapeutics 109 (4), 1104-1115, 2021 | 19 | 2021 |
| Hepatitis E infection among Ghanaians: a systematic review R Ofori-Asenso, AA Agyeman Infectious Diseases of Poverty 6, 1-6, 2017 | 10 | 2017 |
| Understanding cross over and parallel group studies in drug research R Ofori-Asenso, AA Agyeman Precision Medicine 2, e1046, 2015 | 9 | 2015 |
| Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients JF Standing, L Buggiotti, JA Guerra-Assuncao, M Woodall, S Ellis, ... Nature Communications 15 (1), 1652, 2024 | 7 | 2024 |
Richard Ofori-AsensoBiopharmaceuticals MedicalVerified email at astrazeneca.com